MOBIDIAG
2.6.2020 06:02:06 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).
These tests complement the Company’s already available antibody test, Anti-SARS-CoV-2 Rapid Test , that Mobidiag is distributing from its joint venture partner in China, Autobio Diagnostics. Mobidiag is now able to commercially offer a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab based settings.
Due to the high demand for diagnostic devices and tests globally, Mobidiag has ensured that its supply chain and manufacturing capabilities are robust and able to support its customers. This includes, for example, the sourcing and acquisition of various consumables to cover the complete workflow from sample collection to the results (e.g. inhouse production of enzymes and the development of our proprietary mNAT™ Medium sample buffer and collection tubes).
Tuomas Tenkanen, CEO of Mobidiag, said, “With the CE-IVD mark approvals for our Novodiag COVID-19 and Amplidiag COVID-19 molecular diagnostic tests and our distribution of the Anti-SARS-CoV-2 Rapid antibody test, Mobidiag is now able to provide a complete diagnostic solution for the detection of COVID-19 infections across the life cycle of the virus.”
“Mobidiag has leveraged its existing technologies and expertise, including supply chain management and manufacturing, to ensure we are able to deliver a full range of diagnostic solutions to our customers.”
The Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests are able to rapidly and reliably detect COVID-19 infections at an early stage in patients with signs and symptoms of respiratory infection. They have already earlier been granted emergency use authorisation in Finland, Sweden and France. The tests have been designed using dual targets of SARS-CoV-2 (orf1ab & N genes) to include at least one conserved region and one specific region to mitigate the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
The Novodiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs. The test operates using the Novodiag® rapid ‘sample-in, result-out’ system, allowing the on demand fully automated detection of COVID-19 in approximately 1 hour. In addition, Novodiag® solution is a closed system which ensures the protection of laboratory staff and healthcare professionals from possible contamination. The user-friendly nature of the system means that the Novodiag® system can also be used in high risk and hard-to-reach areas and decentralized settings without the need for highly trained personnel.
The Amplidiag® COVID-19 assay complements the Novodiag® COVID-19 on demand test. Based on well-established high-throughput qualitative PCR technology, 48 samples can be processed in less than three hours while running on Mobidiag’s Amplidiag® Easy platform , which enables to clinicians an optimized sample screening process with automated DNA/RNA extraction and PCR plate setup.
In addition to these molecular tests, Mobidiag is distributing an antibody test allowing qualitative determination of Anti-SARS-CoV-2 (IgG and IgM antibodies of SARS-CoV-2) in human serum, plasma or whole blood in less than 15 minutes without any instrumentation. The Anti-SARS-CoV-2 Rapid Test is manufactured by Mobidiag’s joint venture partner in China, Autobio Diagnostics.
Please note that these tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you believe you could be infected by SARS-CoV-2.
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005614/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease30.7.2026 13:01:00 CEST | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for Early Clinical Development, providing practical guidance on the scientific, clinical, and operational factors shaping the development of emerging B-cell depletion therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730139661/en/ B-cell depletion has become an important area of research in autoimmune disease as developers investigate whether deeper and more sustained depletion may support longer periods of remission and potentially influence immune system recovery. Emerging approaches, including in vivo CAR-T therapies and T-cell engagers, are expanding the range of development strategies available beyond established B-cell-targeting treatments. The white paper looks at the early development decisions sponsors face as t
Industrial Info Resources Launches IIR Envoy™ MCP, Bringing Human-Verified Industrial Intelligence Directly Into AI Through Model Context Protocol30.7.2026 13:00:00 CEST | Press release
Model Context Protocol (MCP) connectivity brings 40 years of human-verified energy and industrial intelligence directly into the AI tools professionals already use. Industrial Info Resources (IIR), a leading provider of energy and industrial market intelligence built on primary research and human verification, today announced the launch of IIR Envoy MCP; this new Model Context Protocol connection plugs IIR's authoritative industrial database directly into the AI platforms professionals already use. As an example, with IIR Envoy MCP, an analyst can ask, "What refinery capacity is offline in Europe since this morning's weather event?" or "Which power plants near Houston have upcoming outages?" and receive an instant, source-cited answer drawn from IIR's live data. As AI becomes increasingly embedded in decision-making tools, the quality of AI-generated insights depends entirely on the quality of the underlying data. IIR Envoy MCP was built on that principle. "The information age was abou
120 Million AI Pay Transactions in a Single Week: AI Shopping Agents Move From Theory to Checkout30.7.2026 12:45:00 CEST | Press release
Agentic commerce is beginning to move from forecast to real-world use in some markets. In China, AI agents are already completing purchases at meaningful scale, and analysts now put the global opportunity at $3–5 trillion by 2030. The debate is shifting as early examples show AI shopping agents completing transactions in some markets. According to NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, its global report The Commerce Revolution: Where East Meets West points to agentic commerce moving from experiment toward everyday infrastructure. According to Ant Group, Alipay AI Pay processed more than 120 million transactions during the week of February 5–11, 2026, while Adobe Analytics reported that traffic from generative AI sources to US retail websites increased by 1,200% between July 2024 and February 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730837106/en/ Agentic commerce is beginning to move fr
Quectel Launches FCE870X and FME170X Tri-band Wi-Fi 7 Modules With Bluetooth 6.0 for Set-top Boxes, Gaming Devices and More30.7.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the FCE870X and FME170X tri-band Wi-Fi 7 modules, powered by the Synaptics SYN4384 chipset and designed for set-top boxes, gaming devices, digital signage, VR/AR headsets, smart gateways and other high-performance connected products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730986067/en/ Quectel launches FCE870X and FME170X tri-band Wi-Fi 7 modules with Bluetooth 6.0 for set-top boxes, gaming devices and more The FCE870X and FME170X share the same high-end feature set and differ only in form factor. The FCE870X Wi-Fi 7 module uses a Compact LCC package for embedded designs, while the FME170X Wi-Fi 7 module uses a Compact M.2 package for modular, slot-based systems. Device makers can choose the option that best fits their platform without compromising wireless performance. “These high-end Wi-Fi 7 modules are engineered to run acro
Singapore Selects Thales for Next-generation AI-powered Air Traffic Management System Serving One of Asia’s Busiest Airspaces30.7.2026 10:00:00 CEST | Press release
To address the rapid growth in air traffic, the Civil Aviation Authority of Singapore (CAAS) has selected Thales to develop Singapore’s NexGen Air Traffic Management System (ATMS) and air traffic control radars. Scheduled to enter operational service by 2030, the NexGen ATMS will enable air traffic controllers to provide air traffic control services safely and efficiently, handling up to one million aircraft movements annually. Powered by advanced cybersecurity and Artificial Intelligence technologies, the NexGen ATMS provides an integrated, highly automated environment that enhances controller decision-making, increases operational efficiency, and further strengthens flight safety. The Civil Aviation Authority of Singapore (CAAS) has awarded Thales a landmark contract to develop a new NexGen Air Traffic Management System (ATMS) and air traffic control radars, marking a major step towards a more efficient, safer and more sustainable aviation ecosystem. The NexGen ATMS will replace the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom